 |
|
Enzyme inhibitor takes an unexpected approach toward blocking cancer-promoting protein
September 08, 2009Scientists at Fox Chase Cancer Center have discovered a unique method of attack that may be used to inhibit signaling enzymes called kinases, which often have a role in sustaining drug-resistant cancerous cells. They have confirmed that IPA-3, a small molecular inhibitor of a kinase called PAK1, targets the enzyme's regulatory domain, mimicking how enzymes are naturally regulated within cells.
"Typically, research has focused on ways of blocking the active site of enzymes, the part of the enzyme that performs a particular task," says Jeffrey R. Peterson, Ph.D, an assistant professor Fox Chase's Cancer Genetics and Signaling program and co-author of the article. "The structure of active site, however, is often shared among kinases, which makes it tough to target a particular kinase without accidentally inhibiting a related enzyme."
"By targeting PAK1's specific regulatory domain, IPA-3 is highly selective molecule that takes a more-or-less backdoor approach to shutting down a kinase, " Peterson says. "If we can create drugs that take advantage of this mechanism, we could create new combination therapies that will allow doctors to kill what might otherwise be drug-resistant cells."
Peterson and Julien Viaud, a postdoctoral researcher in the Peterson lab, published their findings in the journal Molecular Cancer Therapeutics, available online now. The researchers previously identified IPA-3 from a screen of 33,000 candidates, and the molecule has since gone on to become an important subject of study by cancer laboratories around the world. In the article, the researchers use a variety of techniques to define how IPA-3 interacts with PAK1.
"We found definitive proof that IPA-3 fit into and binds to PAK1's autoregulatory domain, the part of the enzyme where it can, essentially, shut itself off when necessary," Peterson says. "Our tests also demonstrate that IPA-3 is highly selective for PAK1, which means that it is less likely it will also turn off other kinases unintentionally."
The idea is not entirely without precedent, the cancer drug Gleevec, for example, is unusually selective for its target by binding to a region outside of the active site that is less common among kinases. By defining the regulatory domain as a useful target for inhibition, however, researchers now have a specific place to look when trying to develop new therapeutics for protein regulation, Peterson says.
According to Peterson, small molecule inhibitors such as IPA-3, are promising tools for drug discovery. While IPA-3 itself might not be a suitable as a drug for use in humans, the molecule could form the conceptual basis of a new targeted therapeutic.
Fox Chase Cancer Center
Peterson and Julien Viaud, a postdoctoral researcher in the Peterson lab, published their findings in the journal Molecular Cancer Therapeutics, available online now. The researchers previously identified IPA-3 from a screen of 33,000 candidates, and the molecule has since gone on to become an important subject of study by cancer laboratories around the world. In the article, the researchers use a variety of techniques to define how IPA-3 interacts with PAK1.
"We found definitive proof that IPA-3 fit into and binds to PAK1's autoregulatory domain, the part of the enzyme where it can, essentially, shut itself off when necessary," Peterson says. "Our tests also demonstrate that IPA-3 is highly selective for PAK1, which means that it is less likely it will also turn off other kinases unintentionally."
The idea is not entirely without precedent, the cancer drug Gleevec, for example, is unusually selective for its target by binding to a region outside of the active site that is less common among kinases. By defining the regulatory domain as a useful target for inhibition, however, researchers now have a specific place to look when trying to develop new therapeutics for protein regulation, Peterson says.
According to Peterson, small molecule inhibitors such as IPA-3, are promising tools for drug discovery. While IPA-3 itself might not be a suitable as a drug for use in humans, the molecule could form the conceptual basis of a new targeted therapeutic.
Fox Chase Cancer Center
Kinases Current Events and Kinases News RSSCancers' Sweet Tooth May Be Weakness
The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
New chromosomal abnormality identified in leukemia associated with Down syndrome
Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.
UNC study pinpoints gene controlling number of brain cells
In populating the growing brain, neural stem cells must strike a delicate balance between two key processes - proliferation, in which the cells multiply to provide plenty of starting materials - and differentiation, in which those materials evolve into functioning neurons.
Plants on steroids: Key missing link discovered
Researchers at the Carnegie Institution's Department of Plant Biology have discovered a key missing link in the so-called signaling pathway for plant steroid hormones (brassinosteroids).
Canadian research breakthrough holds promise for development of effective cancer therapies
Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.
Fine-tuning an anti-cancer drug
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes.
What makes stem cells tick?
Investigators at the Burnham Institute for Medical Research (Burnham) and The Scripps Research Institute (TSRI) have made the first comparative, large-scale phosphoproteomic analysis of human embryonic stem cells (hESCs) and their differentiated derivatives.
New microchip technology performs 1,000 chemical reactions at once
Flasks, beakers and hot plates may soon be a thing of the past in chemistry labs. Instead of handling a few experiments on a bench top, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results - literally shrinking the lab down to the size of a thumbnail.
Variations in 5 genes raise risk for most common brain tumors
Common genetic variations spread across five genes raise a person's risk of developing the most frequent type of brain tumor, an international research team reports online in Nature Genetics.
More Kinases Current Events and Kinases News Articles
 |
Kinase Inhibitor Drugs (Wiley Series in Drug Discovery and Development) by Rongshi Li (Author), Jeffrey A. Stafford (Author) A comprehensive resource on case studies of marketed kinase drugs and promising drug trials Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development. In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed... |
|
After Silence Pt. 1 by Kinase Moves the Audio | |
 |
Natto-Kinase - Bottle of 300 by Kastu Natto-Kinase - 300 Tablets Natto-Kinase is a supplement derived from the extracts of non-GMO fermented soybean , onion skin extract, and garlic extract. Natto-kinase is found in fermented soybean, natto. All Katsu Products are manufactured in ISO 9001:2000 quality certified facilities. Organizations certified to the ISO 9001 quality system standards are known for their consistency, reliability, value and customer service. Vitamin K2 has been removed from Katsu Natto-Kinase, while some K1 remains. K2 has been known to congeal blood. This vitamin has been completely removed. K1 is believed to build calcium in the body and fight osteoporosis. Trace amounts of this vitamin remains in this product. Nutrition Breakdown: One Serving (10 tablets) Provides Natto extract 1,875 mg Onion Skin extract... |
 |
After Silence Part 1 Kinase Moves the Audio (Primary Contributor) |
 |
Protein Kinase Protocols (Methods in Molecular Biology) by Alastair D. Reith (Editor) GlaxoSmithKline, Essex, UK. Presents a range of techniques and tools for understanding the roles of specific protein kinases within signalling cascades and for identification and evaluation of novel therapeutic targets. For researchers. |
 |
Jarrow - Creatine Monoydrate, 600 gm 600 gms by Jarrow Formulas Creatine is synthesized in the liver from the amino acidsarginine and glycine and stored in the major muscles, including cardiac and skeletal tissues. Once inside the muscle, creatine is phosphorylated to form creatine phosphate (CP), a high energy substrate that assists in the contraction of the myofibrils (muscle fibers). Creatine Phosphate is utilized to maintain higher levels of ATP (energy molecules) during exercise. Creatine Phosphate maximizes physical performance and reduces exercise fatigue by absorbing hydrogen ions released by muscles in the form of lactic acid. Intense anaerobic exercise, such as weight lifting and sprinting, depletes ATP and greatly increases the demand for creatine. |
 |
Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development (Wiley Series in Drug Discovery and Development) by Ana Martinez (Editor), Ana Castro (Editor), Miguel Medina (Editor), Binghe Wang (Editor) Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development. |
|
|
Sevenless Kinase Moves the Audio (Primary Contributor) |
 |
"ProFluor Src-Family Kinase Assay - Kinase and Phosphatase Assays, Promega - Model PAV1261" by Promega ProFluor Src-Family Kinase Assay - Kinase and Phosphatase Assays, Promega - Model PAV1261 : Kinase-Glo Luminescent Kinase Assays: Determine the activity of purified kinases by quantifying the amount of ATP remaining in solution following a kinase reaction. The assays can be used with a wide range of kinases, including lipid, sugar, alcohol, and |
 |
Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development) by Doriano Fabbro (Editor), Frank McCormick (Editor) Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for... |
| © 2009 BrightSurf.com |